Results 111 to 120 of about 1,927 (159)
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961) [PDF]
, 2010 Joseph J. Eron, JM Livrozet, Philippe Morlat, Adriano Lazzarin, Christine Katlama, Trevor Hawkins, Tamio Fujiwara, Robert L. Cuffe, Cindy Vavro, Julio Montes Santiago, Mounir Ait‐Khaled, Sherene Min, JM Yeo +12 moreopenalex +1 more sourcePharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects [PDF]
, 2011 Akil Jackson, Graeme Moyle, Laura Dickinson, David Back, Saye Khoo, Jessica Taylor, Keerti Gedela, George Abongomera, Brian Gazzard, Marta Boffito +9 moreopenalex +1 more sourceRaltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience
, 2010 Silvia Nozza, Laura Galli, Francesca Visco, Alessandro Soria, Filippo Canducci, Stefania Salpietro, Nicola Gianotti, Alba Bigoloni, Liviana Della Torre, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna +11 moreopenalex +1 more sourcePrevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients [PDF]
, 2011 Isabelle Malet, Marc Wirden, Slim Fourati, Daniele Armenia, Bernard Masquelier, Lavinia Fabeni, Sophie Sayon, Christine Katlama, Carlo Federico Perno, Vincent Cálvez, Anne‐Geneviève Marcelin, Francesca Ceccherini‐Silberstein +11 moreopenalex +1 more sourceTime course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen
, 2010 Constance Delaugerre, Isabelle Charreau, Joséphine Braun, Marie-Laure Néré, Nathalie De Castro, Patrick Yéni, Jade Ghosn, J Aboulker, Jean‐Michel Molina, François Simon +9 moreopenalex +1 more source
